Nebenwirkungen · Benlysta
Benlysta 120 mg powder for concentrate for solution for infusion. Benlysta 400 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 55–56
HOS-123982 · Präparat HOS-095751
55 The data presented in the table below reflect exposure in 674 patients from the three pre-registration clinical studies and 470 patients in the subsequent placebo-controlled study with SLE administered Benlysta intravenously (10 mg/kg body weight over a 1-hour period on Days 0, 14, 28, and then every 28 days for up to 52 weeks), and 556 patients with SLE exposed to Benlysta subcutaneously (200 mg once weekly up to 52 weeks). The safety data presented include data beyond Week 52 in some patients with SLE. The data reflect additional exposure in 224 patients with active lupus nephritis who received Benlysta intravenously (10 mg/kg body weight for up to 104 weeks). Data from post-marketing reports are also included.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T14:51:00Z · SHA-256 c5a3f583695e2640a8d21bbd8da1102adfb181d1d2a9c5afe0028436c8fd2402 · Passage bc9b2f2b7976e5b9fdb52f01e1d2d20c2ea9c76bf552ec647f26424828065bb9 · Zeichen 516–1242 im Abschnitt